Annexon, Inc. (NASDAQ:ANNX - Get Free Report) EVP Ted Yednock sold 5,500 shares of Annexon stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $5.64, for a total value of $31,020.00. Following the completion of the transaction, the executive vice president now owns 10,000 shares in the company, valued at $56,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Ted Yednock also recently made the following trade(s):
- On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.95, for a total value of $32,725.00.
Annexon Stock Down 1.2 %
NASDAQ:ANNX opened at $5.75 on Friday. The firm has a market cap of $531.37 million, a PE ratio of -3.91 and a beta of 1.28. The company's 50-day moving average price is $5.68 and its two-hundred day moving average price is $5.48. Annexon, Inc. has a 12 month low of $1.57 and a 12 month high of $8.40.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter, hitting analysts' consensus estimates of ($0.23). On average, research analysts expect that Annexon, Inc. will post -0.97 EPS for the current fiscal year.
Institutional Inflows and Outflows
Ex-CIA Advisor: “This is How Kamala will Rig the Election”
From Paradigm Press | Ad
A former CIA advisor with close ties to the White House…
Has just released this shocking expose on Kamala’s plan to stop Trump.
Every American needs to prepare now…
Click here now and learn how to prepare.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. increased its position in Annexon by 78.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company's stock valued at $48,000 after acquiring an additional 2,949 shares in the last quarter. Comerica Bank acquired a new position in shares of Annexon during the first quarter worth approximately $72,000. Sandia Investment Management LP bought a new stake in shares of Annexon during the second quarter valued at approximately $49,000. Victory Capital Management Inc. acquired a new stake in shares of Annexon in the second quarter valued at approximately $51,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Annexon in the second quarter valued at approximately $56,000.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on ANNX shares. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price target on shares of Annexon in a report on Tuesday, August 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a report on Wednesday, June 5th. Wells Fargo & Company reduced their target price on shares of Annexon from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, May 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Annexon in a research note on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $15.80.
Check Out Our Latest Report on Annexon
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
